Entera Bio (ENTX) Share-based Compensation (2019 - 2026)
Entera Bio's (ENTX) quarterly Share-based Compensation came in at $672000.0 in Q1 2026, up 11.26% YoY from $604000.0 in Q1 2025, and down 5.35% on a QoQ basis from $710000.0 in Q4 2025.
Entera Bio (ENTX) Share-based Compensation (2019 - 2026) Analysis & Trends
Entera Bio (ENTX) has 8 years of Share-based Compensation data on file, last reported at $672000.0 in Q1 2026.
- Quarterly Share-based Compensation rose 11.26% year-over-year to $672000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.8 million (up 4.53% YoY) and the FY2025 annual result came in at $2.8 million, up 7.59% from the prior year.
- Share-based Compensation fell to $672000.0 in Q1 2026, from $710000.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $964000.0 in Q1 2022 to a low of $110000.0 in Q3 2022.
- A 5-year average of $583176.5 and a median of $566000.0 in 2024 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation sank 82.48% — and 2023, when it surged 248.18%.
- Tracing ENTX's Share-based Compensation over 5 years: stood at $477000.0 in 2022, then plunged by 33.33% to $318000.0 in 2023, then soared by 77.99% to $566000.0 in 2024, then advanced by 25.44% to $710000.0 in 2025, then declined by 5.35% to $672000.0 in 2026.
- The last three Share-based Compensation figures came in at $672000.0 (Q1 2026), $710000.0 (Q4 2025), and $927000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.70 Bn | 131.85 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.75 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.36 Bn | 60.18 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.15 Bn | 54.01 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.88 Bn | 28.57 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.14 Bn | 9.75 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | - |
| 10 | Entera Bio | 165.98 Mn | 154.68 Mn | - | 624,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 624,000.00 |
| Jun 30, 2026 | 624,000.00 |
| Mar 31, 2026 | 672,000.00 |
| Mar 31, 2026 | 672,000.00 |
| Dec 31, 2025 | 710,000.00 |
| Dec 31, 2025 | 710,000.00 |
| Sep 30, 2025 | 927,000.00 |
| Sep 30, 2025 | 927,000.00 |
| Jun 30, 2025 | 509,000.00 |
| Jun 30, 2025 | 509,000.00 |
| Mar 31, 2025 | 604,000.00 |
| Mar 31, 2025 | 604,000.00 |
| Dec 31, 2024 | 566,000.00 |
| Dec 31, 2024 | 566,000.00 |
| Sep 30, 2024 | 928,000.00 |
| Sep 30, 2024 | 928,000.00 |
| Jun 30, 2024 | 598,000.00 |
| Jun 30, 2024 | 598,000.00 |
| Mar 31, 2024 | 464,000.00 |
| Mar 31, 2024 | 464,000.00 |